Glow Up: a single-centre observational study protocol to develop digital biomarkers for prediabetes screening and digital phenotyping
4 affiliations
- 1Digital Health Interventions, School of Medicine, University of St Gallen, St. Gallen, Switzerland
- 2Centre for Digital Health Interventions, Department of Management, Technology and Economics, ETH Zürich, Zürich, Switzerland
- 3Division of Endocrinology and Diabetes, Kantonsspital St.Gallen, HOCH Health Ostschweiz, St. Gallen, Switzerland
- 4Division of General Internal Medicine, Kantonsspital St.Gallen, HOCH Health Ostschweiz, St.Gallen, Switzerland
Abstract
Introduction: Prediabetes, a key precursor to type 2 diabetes, is highly prevalent and underdiagnosed, particularly among adults aged ≥45 years with elevated body mass index (BMI). Early detection is critical because lifestyle interventions can delay or prevent progression to type 2 diabetes. The Glucose Observation and Wearable Use for Prevention (Glow Up) study aims to (1) test the feasibility of a digital biomarker for pre-diabetes screening using wearable- and smartphone-derived lifestyle factors (eg, sleep, physical activity and nutrition patterns) in daily life and to (2) characterise individual- and metabolic subgroup-level variability in lifestyle factors and glycaemic control. Specifically, we aim to examine how lifestyle factors relate to glycaemic status and identify personalised predictors of early metabolic dysregulation.
Methods and analysis: Glow Up is a prospective, single-centre, observational case-control study conducted in Switzerland. Adults (n=200) aged ≥45 years with body mass index (BMI) ≥25 kg/m² will be recruited, including n=100 individuals with pre-diabetes and n=100 age- and sex-matched normoglycaemic controls. Participants will undergo 4 weeks of continuous monitoring using a blinded continuous glucose monitor (CGM) and commercial- and medical-grade wearables; for example, capturing physical activity, sleep and physiological markers (heart rate variability, heart rate and skin temperature), in addition to completing daily image-based meal logs using smartphones. Glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and body anthropometrics will be collected at the enrolment visit (T0) and repeated at follow-up (T3), approximately 5 weeks apart. The primary outcome is glycaemic status at T3, classified from HbA1c and FPG using prespecified thresholds. Secondary outcomes include CGM metrics, lifestyle profiling (sleep, physical activity, stress and nutrition) and adherence to image-based meal logging.
Ethics and dissemination: The study received ethics approval from the Ethics Committee of Eastern Switzerland on 15 May 2025 (BASEC ID: 2025–00972). Written informed consent is obtained from all participants before any study procedures are performed. Findings will be disseminated as articles in international peer-reviewed journals and as posters and oral presentations at national and international conferences. Summaries will be provided to funders and collaborators, and personalised reports to participants.
Trial registration number: NCT07373418.
Related
- Bringing Cardiovascular Prevention into the Community: Protocol for an Observational Study of a Mosque-Based Health Initiative Combining Education and Cardiovascular Screening
- Elevated maternal iron biomarkers and risk of pre-eclampsia in pregnancy: protocol for a systematic review and meta-analysis of observational studies
- Diagnostic and prognostic blood hormone biomarkers in vestibular disorders: protocol for a prospective observational cohort study at a tertiary referral centre in Germany
- A Retrospective Analysis of the Association Between Prediabetes and Biomarkers of Intestinal Permeability in Patients with Prediabetes from Durban, South Africa.
- Diagnostic accuracy of glycated albumin and fructosamine for detecting diabetes and prediabetes in adults: a systematic review and meta-analysis protocol.
BibTeX
@article{brugger2026glow,
title = {{Glow Up: a single-centre observational study protocol to develop digital biomarkers for prediabetes screening and digital phenotyping}},
author = {Victoria Brügger and Magdalena Fuchs and Qiuhan Jin and Benjamin Wirth and Stefan Bilz and Michael Brändle and Tobias Kowatsch and Mia Jovanova},
journal = {BMJ Open},
year = {2026},
month = oct,
doi = {10.1136/bmjopen-2026-119395},
url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-119395},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Glow Up: a single-centre observational study protocol to develop digital biomarkers for prediabetes screening and digital phenotyping
AU - Victoria Brügger
AU - Magdalena Fuchs
AU - Qiuhan Jin
AU - Benjamin Wirth
AU - Stefan Bilz
AU - Michael Brändle
AU - Tobias Kowatsch
AU - Mia Jovanova
PY - 2026
DA - 2026/10/21
JO - BMJ Open
DO - 10.1136/bmjopen-2026-119395
UR - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-119395
AB - Introduction: Prediabetes, a key precursor to type 2 diabetes, is highly prevalent and underdiagnosed, particularly among adults aged ≥45 years with elevated body mass index (BMI). Early detection is critical because lifestyle interventions can delay or prevent progression to type 2 diabetes. The Glucose Observation and Wearable Use for Prevention (Glow Up) study aims to (1) test the feasibility of a digital biomarker for pre-diabetes screening using wearable- and smartphone-derived lifestyle factors (eg, sleep, physical activity and nutrition patterns) in daily life and to (2) characterise individual- and metabolic subgroup-level variability in lifestyle factors and glycaemic control. Specifically, we aim to examine how lifestyle factors relate to glycaemic status and identify personalised predictors of early metabolic dysregulation. Methods and analysis: Glow Up is a prospective, single-centre, observational case-control study conducted in Switzerland. Adults (n=200) aged ≥45 years with body mass index (BMI) ≥25 kg/m² will be recruited, including n=100 individuals with pre-diabetes and n=100 age- and sex-matched normoglycaemic controls. Participants will undergo 4 weeks of continuous monitoring using a blinded continuous glucose monitor (CGM) and commercial- and medical-grade wearables; for example, capturing physical activity, sleep and physiological markers (heart rate variability, heart rate and skin temperature), in addition to completing daily image-based meal logs using smartphones. Glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and body anthropometrics will be collected at the enrolment visit (T0) and repeated at follow-up (T3), approximately 5 weeks apart. The primary outcome is glycaemic status at T3, classified from HbA1c and FPG using prespecified thresholds. Secondary outcomes include CGM metrics, lifestyle profiling (sleep, physical activity, stress and nutrition) and adherence to image-based meal logging. Ethics and dissemination: The study received ethics approval from the Ethics Committee of Eastern Switzerland on 15 May 2025 (BASEC ID: 2025–00972). Written informed consent is obtained from all participants before any study procedures are performed. Findings will be disseminated as articles in international peer-reviewed journals and as posters and oral presentations at national and international conferences. Summaries will be provided to funders and collaborators, and personalised reports to participants. Trial registration number: NCT07373418.
SN - 2044-6055
SN - 2044-6055
ER -